The in-vitro research indicates that andrographolides administration can prevent liver fibrosis by blocking the TGF-1/Smad2 as well as TLR4/NF-kβ p50 pathways and attenuating the expression of profibrotic and proinflammatory proteins [202]. This evidence concerns the gene TLR4 and Hepatic fibrosis.